公开(公告)号：ZA200606051B

公开(公告)日：2008-04-30

申请号：ZA200606051

申请日：2006-07-21

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： JANE WERLING ,  CHAUBAL MAHESH V ,  KIPP JAMES E ,  RABINOW BARRETT E

IPC: A61K20090101 ,  A61K9/10 ,  A61K9/14 ,  A61K9/51 ,  A61K31/00 ,  A61K31/551 ,  A61K31/7072 ,  A61K31/7076

Abstract: The present invention provides compositions comprising dispersions of anti-retroviral agents and methods of manufacture. The nanosuspensions are made by the process of microprecipitation and energy addition. Preferably, the nanosuspensions are made by the tandem process of microprecipitation-homogenization.

公开(公告)号：SG135189A1

公开(公告)日：2007-09-28

申请号：SG2007060551

申请日：2004-09-22

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： RODRIGUEZ ALFREDO ,  RABINOW BARRETT E ,  DOTY MARK ,  KONKEL JAMIE

IPC: A61L2/00 ,  A61L2/02 ,  A61L2/04 ,  B65B55/02

Abstract: The present invention provides a process for sterilizing a system, preferably a pharmaceutical preparation such as a dispersion of small particles or droplets of a pharmaceutically active compound using high pressure terminal sterilization techniques and products therefrom.

公开(公告)号：BRPI0507308A

公开(公告)日：2007-06-26

申请号：BRPI0507308

申请日：2005-01-21

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： WERLING JANE ,  CHAUBAL MAHESH V ,  KIPP JAMES E ,  RABINOW BARRETT E

IPC: A61K9/10 ,  A61K9/14 ,  A61K9/51 ,  A61K31/00 ,  A61K31/551 ,  A61K31/7072 ,  A61K31/7076

Abstract: The present invention provides compositions comprising dispersions of anti-retroviral agents and methods of manufacture. The nanosuspensions are made by the process of microprecipitation and energy addition. Preferably, the nanosuspensions are made by the tandem process of microprecipitation-homogenization.

公开(公告)号：AU2006291225A1

公开(公告)日：2007-03-22

申请号：AU2006291225

申请日：2006-09-07

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： DOTY MARK J ,  CHAUBAL MAHESH ,  KONKEL JAMIE T ,  RABINOW BARRETT E

IPC: A61K9/10 ,  A61K9/00 ,  A61K9/127 ,  A61K9/14 ,  A61K9/16 ,  A61K47/24 ,  A61K47/34 ,  B01J13/00

公开(公告)号：MXPA06002766A

公开(公告)日：2006-12-14

申请号：MXPA06002766

申请日：2004-09-22

Applicant: BAXTER INT

Inventor： RABINOW BARRETT E ,  RODRIGUEZ ALFREDO ,  DOTY MARK ,  KONKEL JAMIE

IPC: A61L2/00 ,  A61L2/02 ,  A61L2/04 ,  B65B55/02

Abstract: La presente invencion proporciona un proceso para esterilizar un sistema, preferentemente una preparacion farmaceutica tal como una dispersion de particulas pequenas o gotas de un compuesto farmaceuticamente activo utilizando tecnicas de esterilizacion terminal a alta presion y productos de los mismos.

公开(公告)号：CA2540383A1

公开(公告)日：2005-05-26

申请号：CA2540383

申请日：2004-11-03

Applicant: BAXTER INT

Inventor： RABINOW BARRETT E ,  CHAUBAL MAHESH ,  WERLING JANE

IPC: A61K31/337 ,  A61K9/10 ,  A61K9/127 ,  A61K9/133 ,  A61K9/14 ,  A61K9/16 ,  A61K31/12 ,  A61K31/495 ,  A61K31/496 ,  A61K31/55 ,  A61K31/573

Abstract: The present invention is concerned with the formation of submicron particles of an antineoplastic agent, particularly paclitaxel, by precipitating the antineoplastic agent in an aqueous medium to form a pre-suspension followed by homogenization. Surfactants with phospholipids conjugated with a water soluble or hydrophilic polymer such as PEG are used as coating for the particles. The particles produced generally have an average particle size of less than about 1000 nm and are not rapidly soluble.

公开(公告)号：AU2004249172A1

公开(公告)日：2004-12-29

申请号：AU2004249172

申请日：2004-06-15

Applicant: BAXTER INT

Inventor： KIPP JAMES E ,  GENDELMAN HOWARD E ,  RABINOW BARRETT E

IPC: A61K9/00 ,  A61K9/51 ,  A61K47/48

Abstract: The present invention is concerned with delivering a pharmaceutical composition to the brain of a mammalian subject for treating brain diseases or disorders. The process includes the steps of: (i) providing a dispersion of the pharmaceutical composition as particles having an average particle size of from about 150 nm to about 100 microns, and (ii) administering the dispersion to the mammalian subject for delivery to the brain of a portion of the pharmaceutical composition by cells capable of reaching the brain. The dispersion of the pharmaceutical composition as particles, for example, can be phagocytized or adsorbed by the cells prior or subsequent to administration into the mammalian subject. The dispersion of the pharmaceutical composition can be administered to the central nervous system or the vascular system. After administration, the loaded cells transport the pharmaceutical composition as particles into the brain.